Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma

Next Previous
Trial Profile

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sovleplenib (Primary)
  • Indications Chronic lymphocytic leukaemia; Cutaneous B-cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Proof of concept
  • Sponsors Hutchison MediPharma; HUTCHMED

Most Recent Events

  • 10 Apr 2024 Results (As of 14 July 2023, n=47) assessing Safety and efficacy of HMPL-523 presented at the 115th Annual Meeting of the American Association for Cancer Research
  • 05 Apr 2024 According to a HUTCHMED media release, company announces that results from this study will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2024,on April 5 to 10, 2024 in San Diego, California.
  • 08 Feb 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top